Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
CUMBERLAND PHARMACEUTICALS INC (CPIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/03/2023 4 Young Caroline (Director) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.65, valued at $107.3
Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.71, valued at $111.2
Small acquisition of 65 shares @ $1.76, valued at $114.4
Small acquisition of 65 shares @ $1.83, valued at $119
Small acquisition of 65 shares @ $1.84, valued at $119.6
Small acquisition of 23 shares @ $1.82, valued at $41.9
Small acquisition of 55 shares @ $2.03, valued at $111.7
Small acquisition of 55 shares @ $2.12, valued at $116.6
10/03/2023 4 Jones James (Director) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.65, valued at $107.3
Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.72, valued at $111.8
Small acquisition of 65 shares @ $1.76, valued at $114.4
Small acquisition of 65 shares @ $1.83, valued at $119
Small acquisition of 65 shares @ $1.84, valued at $119.6
Small acquisition of 23 shares @ $1.82, valued at $41.9
Small acquisition of 55 shares @ $2.03, valued at $111.7
Small acquisition of 55 shares @ $2.12, valued at $116.6
10/03/2023 4 Krogulski Kenneth (Director) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Small acquisition of 280 shares @ $2.03, valued at $568.4
Small acquisition of 280 shares @ $2.12, valued at $593.6
Small acquisition of 280 shares @ $2.14, valued at $599.2
Small acquisition of 280 shares @ $2.28, valued at $638.4
Small acquisition of 280 shares @ $2.29, valued at $641.2
Small acquisition of 280 shares @ $2.24, valued at $627.2
Small acquisition of 280 shares @ $2.07, valued at $579.6
Small acquisition of 280 shares @ $1.98, valued at $554.4
Small acquisition of 280 shares @ $1.96, valued at $548.8
Small acquisition of 280 shares @ $1.9, valued at $532
10/03/2023 4 KAZIMI A J (Chairman and CEO) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.65, valued at $107.3
Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.68, valued at $109.2
Small acquisition of 65 shares @ $1.71, valued at $111.2
Small acquisition of 65 shares @ $1.76, valued at $114.4
Small acquisition of 65 shares @ $1.83, valued at $119
Small acquisition of 65 shares @ $1.84, valued at $119.6
Small acquisition of 23 shares @ $1.82, valued at $41.9
Small acquisition of 55 shares @ $2.03, valued at $111.7
Small acquisition of 55 shares @ $2.12, valued at $116.6
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
06/30/2023 8-K Other Events  Interactive Data
06/07/2023 8-K Other Events  Interactive Data
06/02/2023 8-K Changes in Registrant's Certifying Accountant  Interactive Data
05/24/2023 8-K Changes in Registrant's Certifying Accountant  Interactive Data
05/16/2023 8-K Other Events  Interactive Data
Docs: "CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS"
05/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Cumberland Pharmaceuticals Reports First Quarter 2023"
04/28/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/04/2023 8-K Other Events  Interactive Data
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/22/2023 ARS Form ARS - Annual Report to Security Holders:
03/21/2023 4 JACOBS JOEY A (Director) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Disposed of 5,000 shares @ $2.75, valued at $13.8k
03/21/2023 4 KAZIMI A J (Chairman and CEO) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Paid exercise price by delivering 37,205 shares @ $1.92, valued at $71.4k
03/21/2023 4 Herman James L (VP and Chief Compliance Office) has filed a Form 4 on CUMBERLAND PHARMACEUTICALS INC
Txns: Paid exercise price by delivering 1,280 shares @ $1.92, valued at $2.5k
03/20/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
03/20/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
03/15/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy